Mcclure Conner

  • Nevertheless, the authors are confident that some vaccine candidates will meet these criteria.BNT162b2 dose in patients with plasma cell disorders.morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody response to COVID-19 vaccination.…[Read more]

  • Mcclure Conner became a registered member 2 years, 8 months ago